Literature DB >> 24284318

Antigenic properties of the HIV envelope on virions in solution.

Krishanu Ray1, Meron Mengistu, Lei Yu, George K Lewis, Joseph R Lakowicz, Anthony L DeVico.   

Abstract

The structural flexibility found in human immunodeficiency virus (HIV) envelope glycoproteins creates a complex relationship between antigenicity and sensitivity to antiviral antibodies. The study of this issue in the context of viral particles is particularly problematic as conventional virus capture approaches can perturb antigenicity profiles. Here, we employed a unique analytical system based on fluorescence correlation spectroscopy (FCS), which measures antibody-virion binding with all reactants continuously in solution. Panels of nine anti-envelope monoclonal antibodies (MAbs) and five virus types were used to connect antibody binding profiles with neutralizing activities. Anti-gp120 MAbs against the 2G12 or b12 epitope, which marks functional envelope structures, neutralized viruses expressing CCR5-tropic envelopes and exhibited efficient virion binding in solution. MAbs against CD4-induced (CD4i) epitopes considered hidden on functional envelope structures poorly bound these viruses and were not neutralizing. Anti-gp41 MAb 2F5 was neutralizing despite limited virion binding. Similar antigenicity patterns occurred on CXCR4-tropic viruses, except that anti-CD4i MAbs 17b and 19e were neutralizing despite little or no virion binding. Notably, anti-gp120 MAb PG9 and anti-gp41 MAb F240 bound to both CCR5-tropic and CXCR4-tropic viruses without exerting neutralizing activity. Differences in the virus production system altered the binding efficiencies of some antibodies but did not enhance antigenicity of aberrant gp120 structures. Of all viruses tested, only JRFL pseudoviruses showed a direct relationship between MAb binding efficiency and neutralizing potency. Collectively, these data indicate that the antigenic profiles of free HIV particles generally favor the exposure of functional over aberrant gp120 structures. However, the efficiency of virion-antibody interactions in solution inconsistently predicts neutralizing activity in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284318      PMCID: PMC3911592          DOI: 10.1128/JVI.03048-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  94 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

Review 2.  The antibody response in HIV-1 infection.

Authors:  D R Burton; D C Montefiori
Journal:  AIDS       Date:  1997       Impact factor: 4.177

3.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

4.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

5.  Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Authors:  Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-13       Impact factor: 11.205

6.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

Review 7.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

9.  Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility.

Authors:  Hillel Haim; Ignacio Salas; Joseph Sodroski
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

10.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.

Authors:  Guang Yang; T Matt Holl; Yang Liu; Yi Li; Xiaozhi Lu; Nathan I Nicely; Thomas B Kepler; S Munir Alam; Hua-Xin Liao; Derek W Cain; Leonard Spicer; John L VandeBerg; Barton F Haynes; Garnett Kelsoe
Journal:  J Exp Med       Date:  2013-01-28       Impact factor: 14.307

View more
  31 in total

1.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.

Authors:  Pinghuang Liu; Latonya D Williams; Xiaoying Shen; Mattia Bonsignori; Nathan A Vandergrift; R Glenn Overman; M Anthony Moody; Hua-Xin Liao; Daniel J Stieh; Kerrie L McCotter; Audrey L French; Thomas J Hope; Robin Shattock; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 3.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

4.  CD4 mimetics sensitize HIV-1-infected cells to ADCC.

Authors:  Jonathan Richard; Maxime Veillette; Nathalie Brassard; Shilpa S Iyer; Michel Roger; Loïc Martin; Marzena Pazgier; Arne Schön; Ernesto Freire; Jean-Pierre Routy; Amos B Smith; Jongwoo Park; David M Jones; Joel R Courter; Bruno N Melillo; Daniel E Kaufmann; Beatrice H Hahn; Sallie R Permar; Barton F Haynes; Navid Madani; Joseph G Sodroski; Andrés Finzi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

Review 5.  Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.

Authors:  George K Lewis; Yongjun Guan; Roberta Kamin-Lewis; Mohammad Sajadi; Marzena Pazgier; Anthony L Devico
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

6.  Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.

Authors:  Kai Yang; Jie Lan; Nicole Shepherd; Ningjie Hu; Yanyan Xing; Daniel Byrd; Tohti Amet; Corlin Jewell; Samir Gupta; Carole Kounga; Jimin Gao; Qigui Yu
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

Review 7.  Molecular determinants of the ratio of inert to infectious virus particles.

Authors:  P J Klasse
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

8.  Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection.

Authors:  Aaron Christensen-Quick; Mark Lafferty; Lingling Sun; Luigi Marchionni; Anthony DeVico; Alfredo Garzino-Demo
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

9.  Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Authors:  Priyamvada Acharya; William D Tolbert; Neelakshi Gohain; Xueji Wu; Lei Yu; Tongyun Liu; Wensheng Huang; Chih-Chin Huang; Young Do Kwon; Robert K Louder; Timothy S Luongo; Jason S McLellan; Marie Pancera; Yongping Yang; Baoshan Zhang; Robin Flinko; James S Foulke; Mohammad M Sajadi; Roberta Kamin-Lewis; James E Robinson; Loïc Martin; Peter D Kwong; Yongjun Guan; Anthony L DeVico; George K Lewis; Marzena Pazgier
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

10.  A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies.

Authors:  Shilei Ding; Maxime Veillette; Mathieu Coutu; Jérémie Prévost; Louise Scharf; Pamela J Bjorkman; Guido Ferrari; James E Robinson; Christina Stürzel; Beatrice H Hahn; Daniel Sauter; Frank Kirchhoff; George K Lewis; Marzena Pazgier; Andrés Finzi
Journal:  J Virol       Date:  2015-12-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.